Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Michael Diamond and James Case.
Michael Diamond
Connection Strength
6.192
James Case
  1. Ultrapotent miniproteins targeting the SARS-CoV-2 receptor-binding domain protect against infection and disease. Cell Host Microbe. 2021 07 14; 29(7):1151-1161.e5.
    View in: PubMed
    Score: 0.953
  2. On the road to ending the COVID-19 pandemic: Are we there yet? Virology. 2021 05; 557:70-85.
    View in: PubMed
    Score: 0.931
  3. Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice. Cell Host Microbe. 2020 09 09; 28(3):465-474.e4.
    View in: PubMed
    Score: 0.895
  4. Growth, detection, quantification, and inactivation of SARS-CoV-2. Virology. 2020 09; 548:39-48.
    View in: PubMed
    Score: 0.887
  5. In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. Nature. 2021 08; 596(7870):103-108.
    View in: PubMed
    Score: 0.238
  6. A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques. Cell Rep Med. 2021 04 20; 2(4):100230.
    View in: PubMed
    Score: 0.234
  7. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat Med. 2021 04; 27(4):717-726.
    View in: PubMed
    Score: 0.233
  8. Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection. Cell. 2021 04 01; 184(7):1804-1820.e16.
    View in: PubMed
    Score: 0.232
  9. A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2. Cell. 2020 10 01; 183(1):169-184.e13.
    View in: PubMed
    Score: 0.225
  10. Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. Cell Host Microbe. 2020 09 09; 28(3):475-485.e5.
    View in: PubMed
    Score: 0.223
  11. A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies. Cell. 2020 08 06; 182(3):744-753.e4.
    View in: PubMed
    Score: 0.222
  12. Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques. Proc Natl Acad Sci U S A. 2021 09 21; 118(38).
    View in: PubMed
    Score: 0.061
  13. A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants. Immunity. 2021 09 14; 54(9):2159-2166.e6.
    View in: PubMed
    Score: 0.060
  14. Assessment of serological assays for identifying high titer convalescent plasma. Transfusion. 2021 09; 61(9):2658-2667.
    View in: PubMed
    Score: 0.060
  15. A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters. Cell Rep. 2021 07 20; 36(3):109400.
    View in: PubMed
    Score: 0.060
  16. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature. 2021 08; 596(7870):109-113.
    View in: PubMed
    Score: 0.060
  17. The antigenic anatomy of SARS-CoV-2 receptor binding domain. Cell. 2021 04 15; 184(8):2183-2200.e22.
    View in: PubMed
    Score: 0.058
  18. Association between SARS-CoV-2 Neutralizing Antibodies and Commercial Serological Assays. Clin Chem. 2020 12 01; 66(12):1538-1547.
    View in: PubMed
    Score: 0.057
  19. Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion. Proc Natl Acad Sci U S A. 2020 12 15; 117(50):32105-32113.
    View in: PubMed
    Score: 0.057
  20. Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. Nat Immunol. 2020 12; 21(12):1506-1516.
    View in: PubMed
    Score: 0.057
  21. Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. Science. 2020 11 20; 370(6519):950-957.
    View in: PubMed
    Score: 0.057
  22. De novo design of picomolar SARS-CoV-2 miniprotein inhibitors. Science. 2020 10 23; 370(6515):426-431.
    View in: PubMed
    Score: 0.056
  23. Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2. Proc Natl Acad Sci U S A. 2020 08 25; 117(34):20803-20813.
    View in: PubMed
    Score: 0.056
  24. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. 2020 08; 584(7821):443-449.
    View in: PubMed
    Score: 0.056
  25. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med. 2020 09; 26(9):1422-1427.
    View in: PubMed
    Score: 0.056
  26. A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection. J Immunol. 2020 08 15; 205(4):915-922.
    View in: PubMed
    Score: 0.056
  27. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020 07; 583(7815):290-295.
    View in: PubMed
    Score: 0.055
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.